Rakovina Therapeutics chief scientific officer Mads Daugaard joined Steve Darling from Proactive to share news the company has shared new data at the American Association of Cancer Research meeting in Orlando, Florida.
Daugaard tells Proactive the data describes the progress of the company’s kt-3000 drug development program. The data shows the kt-3000 prototype lead candidate exhibits higher PARP-1 versus PARP-2 selectivity compared to the FDA-approved PARP inhibitor, olaparib.
Daugaard also says the kt-3000 lead candidate effectively reduced lung metastases in mice inoculated with Ewing sarcoma tumor cells.
#proactiveinvestors #rakovinatherapeuticsinc #tsxv #rkv #cancer #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
